The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1131-1140

  Shi, Yi Kang ^a   Li, Zhong Hua ^b   Han, Xi Qian ^a   Yi, Ji Hu ^c   Wang, Zhen Hua ^b   Hou, Jing Li ^b   Feng, Cong Ran ^b   Fang, Qing Hong ^b   Wang, Hui Hui ^b   Zhang, Peng Fei ^b   Wang, Feng Shan ^a   Shen, Jie ^b   Wang, Peng ^b,d  

^a SHANDONG UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c Shandong Academy of Occupational Health and Occupational Medicine   (China)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; HDACi; SAHA; Taxol

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN D1; HISTONE H3; PACLITAXEL; PROTEIN BAX; PROTEIN P21; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS;

EID: 78149414571     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1455-1     Document Type: Article

References (41)

1. KB Glaser 2007 HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 659 671 1:CAS:528:DC%2BD2sXotlajsr8%3D 10.1016/j.bcp.2007.04.007 17498667 (Pubitemid 47096639)
2. Q Zhou R Chaerkady PG Shaw TW Kensler A Pandey NE Davidson 2010 Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells Proteomics 10 1029 1039 1:CAS:528:DC%2BC3cXis1ynt78%3D 20049865
3. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 1:CAS:528: DC%2BD28XptVCltrY%3D 10.1038/nrd2133 16955068 (Pubitemid 44348499)
4. D Neureiter S Zopf T Leu O Dietze C Hauser-Kronberger EG Hahn C Herold M Ocker 2007 Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models Scand J Gastroenterol 42 103 116 1:CAS:528:DC%2BD2sXhvVanurk%3D 10.1080/00365520600874198 17190770 (Pubitemid 46033053)
5. RK Lindemann A Newbold KF Whitecross LA Cluse AJ Frew L Ellis S Williams AP Wiegmans AE Dear CL Scott M Pellegrini A Wei VM Richon PA Marks SW Lowe MJ Smyth RW Johnstone 2007 Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma Proc Natl Acad Sci USA 104 8071 8076 1:CAS:528:DC%2BD2sXmtFSnu7s%3D 10.1073/pnas.0702294104 17470784 (Pubitemid 47185877)
6. LA Cohen PA Marks RA Rifkind S Amin D Desai B Pittman VM Richon 2002 Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors Anticancer Res 22 1497 1504 1:CAS:528:DC%2BD38XmsFWluro%3D 12168829
7. G Imre V Gekeler A Leja T Beckers M Boehm 2006 Histone deacetylase inhibitors suppress the inducibility of nuclear factorkappaB by tumor necrosis factor-alpha receptor-1 down-regulation Cancer Res 66 5409 5418 1:CAS:528:DC%2BD28XksF2itr8%3D 10.1158/0008-5472.CAN-05-4225 16707469 (Pubitemid 43844968)
8. BS Mann JR Johnson MH Cohen R Justice R Pazdur 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247 1252 1:CAS:528:DC%2BD2sXhtlOmurrL 10.1634/theoncologist.12- 10-1247 17962618 (Pubitemid 350106355)
9. AJ Frew RW Johnstone JE Bolden 2009 Enhancing the apoptotic and therapeutic effects of HDAC inhibitors Cancer Lett 280 123 133 10.1016/j.canlet.2009.02.042
10. Y Mo Y Gan S Song J Johnston X Xiao MG Wientjes JL Au 2003 Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach Cancer Res 63 579 585 1:CAS:528:DC%2BD3sXosVyjsQ%3D%3D 12566299
11. M Kavallaris 2010 Microtubules resistance to tubulin-binding agents Nat Rev Cancer 10 194 204 1:CAS:528:DC%2BC3cXhvVKrtbg%3D 10.1038/nrc2803 20147901
12. TK Owonikoko SS Ramalingam B Kanterewicz TE Balius CP Belani PA Hershberger 2010 Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells Int J Cancer 126 743 755 1:CAS:528: DC%2BD1MXhsFGjs7bO 10.1002/ijc.24759 19621389
13. CS Dietrich 3rd VL Greenberg CP DeSimone SC Modesitt JR Van Nagell R Craven SG Zimmer 2010 Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines Gynecol Oncol 116 126 130 10.1016/j.ygyno.2009.09.039 19875160
14. AL Cooper VL Greenberg PS Lancaster JR Van Nagell Jr SG Zimmer SC Modesitt 2007 In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer Gynecol Oncol 104 596 601 1:CAS:528:DC%2BD2sXitFOgsLc%3D 10.1016/j.ygyno.2006.09.011 17049973 (Pubitemid 46240243)
15. SC Dowdy S Jiang XC Zhou X Hou F Jin KC Podratz SW Jiang 2006 Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells Mol Cancer Ther 5 2767 2776 1:CAS:528:DC%2BD28Xht1els7bO 10.1158/1535-7163.MCT-06- 0209 17121923 (Pubitemid 44849003)
16. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4 6382953
17. MV Blagosklonny R Robey DL Sackett L Du F Traganos Z Darzynkiewicz T Fojo SE Bates 2002 Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol Cancer Ther 1 937 941 1:CAS:528:DC%2BD3sXmvFOntg%3D%3D 12481415
18. Y Zhang N Li C Caron G Matthias D Hess S Khochbin P Matthias 2003 HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J 22 1168 1179 1:CAS:528:DC%2BD3sXit1yls7c%3D 10.1093/emboj/cdg115 12606581 (Pubitemid 36313600)
19. BS Mann JR Johnson MH Cohen R Justice R Pazdur 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247 1252 1:CAS:528:DC%2BD2sXhtlOmurrL 10.1634/theoncologist.12- 10-1247 17962618 (Pubitemid 350106355)
20. VR Panday MT Huizing LJ van Warmerdam RC Dubbelman I Mandjes JH Schellens WW Huinink JH Beijnen 1998 Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer Pharmacol Res 38 231 236 1:CAS:528:DyaK1cXmsVCls7w%3D 10.1006/phrs.1998.0360 9782075 (Pubitemid 28418290)
21. MT Huizing AC Keung H Rosing V van der Kuij WW ten Bokkel Huinink IM Mandjes AC Dubbelman HM Pinedo JH Beijnen 1993 Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients J Clin Oncol 11 2127 2135 1:STN:280:DyaK2c%2FksFyitA%3D%3D 7901342
22. L Gianni CM Kearns A Giani G Capri L Viganó A Lacatelli G Bonadonna MJ Egorin 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190 1:STN:280:DyaK2M%2Fps12ntg%3D%3D 7799018
23. T Ohtsu Y Sasaki T Tamura Y Miyata H Nakanomyo Y Nishiwaki N Saijo 1995 Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion Clin Cancer Res 1 599 606 1:STN:280: DyaK1M%2FjsVymsQ%3D%3D 9816021
24. H Steed MB Sawyer 2007 Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel Pharmacogenomics 8 803 815 1:CAS:528: DC%2BD2sXnvVertr4%3D 10.2217/14622416.8.7.803 17638515 (Pubitemid 47288979)
25. MS Finnin JR Donigian A Cohen VM Richon RA Rifkind PA Marks R Breslow NP Pavletich 1999 Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 188 193 1:CAS:528:DyaK1MXlvFKgtrc%3D 10.1038/43710 10490031 (Pubitemid 29436325)
26. PN Munster T Troso-Sandoval N Rosen R Rifkind PA Marks VM Richon 2001 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 8492 8497 1:CAS:528:DC%2BD3MXptFCkur8%3D 11731433
27. P Bali SwabyR PranpatM W Fiskus H Yamaguchi M Balasis K Rocha HG Wang V Richon K Bhalla 2005 Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2 Clin Cancer Res 11 6382 6389 1:CAS:528:DC%2BD2MXpslansbk%3D 10.1158/1078-0432.CCR-05-0344 16144943 (Pubitemid 41262970)
28. Q Zhou PG Shaw NE Davidson 2009 Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells Breast Cancer Res Treat 117 443 451 1:CAS:528:DC%2BD1MXpvF2gsLY%3D 10.1007/s10549-008-0148-5 18683042
29. M De los Santos O Martínez-Iglesias A Aranda 2007 Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocr Relat Cancer 14 1021 1028 10.1677/ERC-07-0144 (Pubitemid 351252433)
30. J Sonnemann J Gänge S Pilz C Stötzer R Ohlinger A Belau G Lorenz JF Beck 2006 Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients BMC Cancer 6 183 10.1186/1471-2407-6-183 16834771 (Pubitemid 46277107)
31. AA Ruefli D Bernhard KM Tainton R Kofler MJ Smyth RW Johnstone 2002 Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells Int J Cancer 99 292 298 1:CAS:528:DC%2BD38XivFyrs7c%3D 10.1002/ijc.10327 11979447 (Pubitemid 34309489)
32. MJ Peart KM Tainton AA Ruefli AE Dear KA Sedelies LA O'Reilly NJ Waterhouse JA Trapani RW Johnstone 2003 Novel mechanisms of apoptosis induced by histone deacetylase inhibitors Cancer Res 63 4460 4471 1:CAS:528: DC%2BD3sXmtFersrs%3D 12907619
33. D Marchion P Münster 2007 Development of histone deacetylase inhibitors for cancer treatment Expert Rev Anticancer Ther 7 583 598 1:CAS:528:DC%2BD2sXkt1Wqsrk%3D 10.1586/14737140.7.4.583 17428177 (Pubitemid 46690964)
34. J Tan S Cang Y Ma RL Petrillo D Liu 2010 Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents J Hematol Oncol 3 5 10.1186/1756-8722-3-5 20132536
35. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 621 681 1:CAS:528:DC%2BD28XhtVOhtLfL 10.1124/pr.58.3.10 16968952 (Pubitemid 44403686)
36. K Torres SB Horwitz 1998 Mechanisms of Taxol-induced cell death are concentration dependent Cancer Res 58 3620 3626 1:CAS:528:DyaK1cXlsFajt7o%3D 9721870
37. QT Luong J O'Kelly GD Braunstein JM Hershman HP Koeffler 2006 Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo Clin Cancer Res 12 5570 5577 1:CAS:528:DC%2BD28XpvFShtrk%3D 10.1158/1078-0432.CCR-06-0367 17000694 (Pubitemid 44497275)
38. MV Blagosklonny TW Schulte P Nguyen EG Mimnaugh J Trepel L Neckers 1995 Taxol induction of p21WAF1 and p53 requires c-raf-1 Cancer Res 55 4623 4626 1:CAS:528:DyaK2MXoslWmsLs%3D 7553639
39. S Etienne-Manneville A Hall 2002 Rho GTPases in cell biology Nature 420 629 635 1:CAS:528:DC%2BD38XpsVSitbw%3D 10.1038/nature01148 12478284 (Pubitemid 36764489)
40. T Wittmann CM Waterman-Storer 2001 Cell motility: can Rho GTPases and microtubules point the way? J Cell Sci 114 3795 3803 1:CAS:528: DC%2BD3MXosl2rtb0%3D 11719546
41. AB Niculescu III X Chen M Smeets L Hengst C Prives SI Reed 1998 Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication Mol Cell Biol 18 629 643 1:CAS:528:DyaK1cXjtFCqtA%3D%3D 9418909